These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 27595394)

  • 1. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
    Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
    Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.
    Cho H; Du X; Rizzi JP; Liberzon E; Chakraborty AA; Gao W; Carvo I; Signoretti S; Bruick RK; Josey JA; Wallace EM; Kaelin WG
    Nature; 2016 Nov; 539(7627):107-111. PubMed ID: 27595393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
    Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
    Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
    Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
    Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of
    Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
    Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
    Tella SH; Taïeb D; Pacak K
    Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
    Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
    Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
    Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HIF2α in Clear-Cell Renal Cell Carcinoma.
    Ricketts CJ; Crooks DR; Linehan WM
    Cancer Cell; 2016 Oct; 30(4):515-517. PubMed ID: 27728802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-[(1
    Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM
    J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K; Zhang N; Zhang K; Na Y
    Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
    Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
    Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
    Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
    Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl Hydroxylase 3 Knockdown Accelerates
    Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
    Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
    J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC.
    Gregoris F; Minervini G; Tosatto SCE
    Genes (Basel); 2024 Sep; 15(9):. PubMed ID: 39336758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
    Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.